Leishmaniasis: Current Treatment and Prospects for New Drugs and Vaccines, Current Medicinal Chemistry, vol.16, issue.5, pp.599-614, 2009. ,
DOI : 10.2174/092986709787458489
Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates, Clinical Immunology, vol.109, issue.1, pp.64-71, 2003. ,
DOI : 10.1016/S1521-6616(03)00202-X
New horizons in adjuvants for vaccine development, Trends in Immunology, vol.30, issue.1, pp.23-32, 2009. ,
DOI : 10.1016/j.it.2008.09.006
Vaccines for leishmaniasis in the fore coming 25 years, Vaccine, vol.26, issue.14, pp.1709-1724, 2008. ,
DOI : 10.1016/j.vaccine.2008.01.023
Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine, Current Genomics, vol.4, issue.3, pp.253-261, 2003. ,
DOI : 10.2174/1389202033490439
A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major, Vaccine, vol.19, issue.25-26, pp.3369-75, 2001. ,
DOI : 10.1016/S0264-410X(01)00081-0
Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of ., Vaccine, vol.23, issue.28, pp.3716-3741, 2005. ,
DOI : 10.1016/j.vaccine.2005.02.009
Leishmania infantum: Prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice, Experimental Parasitology, vol.118, issue.3, pp.393-401, 2008. ,
DOI : 10.1016/j.exppara.2007.10.004
URL : https://hal.archives-ouvertes.fr/pasteur-00796762
Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy, Advanced Drug Delivery Reviews, vol.61, issue.3, pp.233-242, 2009. ,
DOI : 10.1016/j.addr.2008.12.014
Solid lipid nanoparticles (SLN) for controlled drug delivery ?????? a review of the state of the art, European Journal of Pharmaceutics and Biopharmaceutics, vol.50, issue.1, pp.161-177, 2000. ,
DOI : 10.1016/S0939-6411(00)00087-4
Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant, Pharmaceutical Research, vol.14, issue.4, pp.458-462, 1997. ,
DOI : 10.1023/A:1012043315093
Lipid nanoparticles for parenteral delivery of actives, European Journal of Pharmaceutics and Biopharmaceutics, vol.71, issue.2, pp.161-172, 2009. ,
DOI : 10.1016/j.ejpb.2008.09.003
Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer, European Journal of Pharmaceutics and Biopharmaceutics, vol.57, issue.2, pp.155-162, 2004. ,
DOI : 10.1016/j.ejpb.2003.10.015
Solid lipid nanoparticles: Formulation factors affecting cell transfection capacity, International Journal of Pharmaceutics, vol.339, issue.1-2, pp.261-268, 2007. ,
DOI : 10.1016/j.ijpharm.2007.03.015
Solid lipid nanoparticles as potential tools for gene therapy: In vivo protein expression after intravenous administration, International Journal of Pharmaceutics, vol.385, issue.1-2, 2009. ,
DOI : 10.1016/j.ijpharm.2009.10.020
Requirements for Th1-dependent immunity against infection with L. major. Microbs and Infection, pp.1102-1109, 2004. ,
Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA, Journal of Controlled Release, vol.77, issue.3, pp.345-355, 2001. ,
DOI : 10.1016/S0168-3659(01)00506-5
Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization, Journal of Microencapsulation, vol.10, issue.1, pp.173-184, 1998. ,
DOI : 10.1016/0163-7258(84)90035-4
Application of Novel Solid Lipid Nanoparticle (SLN)-Gene Vector Formulations Based on a Dimeric HIV-1 TAT-Peptide in Vitro and in Vivo, Pharmaceutical Research, vol.21, issue.9, pp.1662-1669, 2004. ,
DOI : 10.1023/B:PHAM.0000041463.56768.ec
Evaluation of polyplexes as gene transfer agents, Journal of Controlled Release, vol.73, issue.2-3, pp.401-416, 2001. ,
DOI : 10.1016/S0168-3659(01)00357-1
Intracellular uptake and release of poly(ethyleneimine)-co-poly(methyl methacrylate) nanoparticle/pDNA complexes for gene delivery, International Journal of Pharmaceutics, vol.311, issue.1-2, pp.209-214, 2006. ,
DOI : 10.1016/j.ijpharm.2005.12.035
Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: Characterization and ability to bind the pEGFP-plasmid, European Journal of Pharmaceutics and Biopharmaceutics, vol.67, issue.2, pp.320-328, 2007. ,
DOI : 10.1016/j.ejpb.2007.02.006
pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles, International Journal of Pharmaceutics, vol.389, issue.1-2, pp.254-261, 2010. ,
DOI : 10.1016/j.ijpharm.2010.01.030